Great thread, thanks for sharing
The 30 or so bona fide anti-ageing companies that exist are more interested in developing their own proprietary therapies than readily accessible drugs such as Rapamycin, metformin, dasatinib and quercetin. Until additional funding can be found, this means that safe, affordable drugs with the potential to slow ageing and extend the healthspan are not being properly explored
James - I agree that this is an issue. Its great to have the commercial focus on anti-aging drugs - but its going to take 20+ years for those results to filter down to most people. I think the NIH / National Institute on Aging needs to develop a ITP RCT program focused on identifying generic drug candidates for anti-aging and fund some major phase 2 clinical trials for age mitigation.
The latest Matt Kaeberlein Interview. (Haven’t watched it yet.)
Watch this talk – in conversation with a16z crypto partner @guywuolletjr – to learn about Kaeberlein’s views on promoting healthspan, and improving quality of life for people (and companion animals)… especially if your new year’s resolutions are focused on health and longevity!
Was this the survey of people just taking rapa? Or something else?
Here’s the lecture he gave prior to the interview:
